Rituximab and antineutrophil cytoplasmic antibody-associated vasculitis: Granulomatous disease more resistant than vasculitis disease?

Journal of Clinical Rheumatology

Volumn 14, Issue 2, 2008, Pages 61-64

  Wong, Christopher F ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; BRONCHUS STENOSIS; BRONCHUS TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EDITORIAL; GRANULOMATOUS INFLAMMATION; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; LOWER RESPIRATORY TRACT INFECTION; LUNG NODULE; MENINGIOMA; ORBIT GRANULOMA; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; SEPSIS; STAPHYLOCOCCUS INFECTION; SUBGLOTTIC STENOSIS; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; GRANULOMA; HUMANS; SALVAGE THERAPY; WEGENER GRANULOMATOSIS;

EID: 42049107150     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31816b449e     Document Type: Editorial

References (40)

1. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Eng J Med. 2003;349:36-44.
2. Sneller MC. Rituximab and Wegener's granulomatosis: are B-cells a target in vasculitis treatment. Arthritis Rheum. 2005;52:1-5.
3. Voswinkel J, Mueller A, Kraemer JA, et al. B-lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis. 2006;65:859-864.
4. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B-cell dependent. J Immunol. 2001;167:4710-4718.
5. Brulhart L, Ciurea A, Finckh A, et al. Efficacy of B cell depletion in rheumatoid arthritis patients refractory to anti-tumour necrosis factor (TNF): an open label observational study. Ann Rheum Dis. 2006;65:1255-1257.
6. Emery P, Fleischmann R, Filipowicz-SoSnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double blind, placebo-controlled, dose ranging trial. Arthritis Rheum. 2006;54:1390-1400.
7. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-2806.
8. Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B-cells but lacking serum antibody reveals an antibody-independent role for B-cells in murine lupus. J Exp Med. 1999;189:1639-1648.
9. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-2589.
10. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007;17:191-197.
11. Cambridge G, Leandro MJ, Edwards JC, et al. (2003) Serologic changes following B-lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146-2154.
12. Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titre in patients with Wegener's granulomatosis. Arthritis Rheum. 1993;36:365-337.
13. Specks U, Freeze FC, McDonald TJ, et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001;44:2836-2840.
14. Ferraro AJ, Day CJ, Drayson MT, et al. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant. 2005;20:622-625.
15. Omdal R, Wildhagen K, Hansen T, et al. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol. 2005;34:229-232.
16. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.
17. Bachmeyer C, Cadranel JF, Demontis R. Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis. Nephrol Dial Transplant. 2005;20:1274.
18. Kallenbach M, Duan H, Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract. 2005;99:c92-c96.
19. Tamura N, Matsudaira R, Hirashima M, et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med. 2007;46:409-414.
20. Keogh KA, Wylam ME, Stone JH, et al. Induction of remission by B-lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:262-268.
21. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med. 2005;257:540-548.
22. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173:180-187.
23. Aries PM, Hellmich B, Both M, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2006;65:853-858.
24. Stasi R, Stipa E, Del Poeta G, et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with Rituximab. Rheumatology (Oxford). 2006;45:1432-1436.
25. Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 2006;54:2970-2982.
26. Brihaye B, Aouba A, Pagnoux C, et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S23-S27.
27. Henes JC, Fritz J, Koch S, et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis - additive effects of a maintenance treatment with leflunomide. Clin Rheumatol. 2007;26:1711-1715.
28. Aries PM, Hellmich B, Reinhold-Keller E, et al. High dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis. Rheumatology. 2004;43:1307-1308.
29. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (RIT) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
30. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.
31. Sanchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N. Effect of rituximab on refractory Wegener's granulomatosis with predominant granulomatous disease. J Clin Rheumatol. In press.
32. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with lefluonomide in Wegener's granulomatosis. Rheumatology 2004;43:315-320.
33. Goblin JM, Fervenza FC, Keogh KA, et al. Longterm use of rituximab in patients with chronically relapsing Wegener's Granulomatosis. American Society Nephrology Conference 2007; SA-FC109.
34. Kolstad A, Holte H, Fosså A, et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 2007;92:139-140.
35. Wong CF, Corbett S, Darroch J, et al. Rituximab and refractory ANCA associated vasculitis: is low CD4 count detrimental? Abstract in Renal Association and British Renal Society in Harrogate, UK, May 2006.
36. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356:2751-2752.
37. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511-1513.
38. Kemper MJ, Moller K, Lugwig K, et al. Rituximab in treatment of refractory steroid sensitive nephrotic syndrome (abstract). Pediatr Nephrol. 2006;21:1528.
39. FDA Public Health Advisory. Life-threatening brain infection in patients with Systemic Lupus Erythematosus after Rituxan (Rituximab) treatment. December 18, 2006. Available at: http://www.fda.gov/cder/drug/advisory/rituximab.htm.
40. Wong CF. Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol Dial Transplant. 2007;22:32-36.